Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.00263 USD | +9.58% | 0.00% | -70.11% |
2023 | Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
2023 | Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval | CI |
Sales 2021 | 0.07 6.09 | Sales 2022 | 0.14 11.28 | Capitalization | 3.5M 292M |
---|---|---|---|---|---|
Net income 2021 | -3M -250M | Net income 2022 | -18M -1.5B | EV / Sales 2021 | 11,24,21,804 x |
Net Debt 2021 | 7.1M 591M | Net Debt 2022 | 7.15M 596M | EV / Sales 2022 | 7,86,89,579 x |
P/E ratio 2021 |
-0.3
x | P/E ratio 2022 |
-0.14
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 77.47% |
1 day | +9.58% | ||
Current month | -16.13% | ||
1 month | -16.13% | ||
3 months | -58.06% | ||
6 months | -80.00% | ||
Current year | -70.11% |
Managers | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 01/12/01 |
Don Calabria
COO | Chief Operating Officer | 53 | - |
Steven Barnes
IRC | Investor Relations Contact | - | 01/14/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 01/12/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.00263 | +9.58% | 12,836 |
25/24/25 | 0.0024 | -4.00% | 100,000 |
24/24/24 | 0.0025 | 0.00% | 390,599 |
23/24/23 | 0.0025 | 0.00% | 153,000 |
22/24/22 | 0.0025 | -4.58% | 59,990 |
Delayed Quote OTC Markets, April 26, 2024 at 08:15 pm IST
More quotes1st Jan change | Capi. | |
---|---|---|
-70.11% | 919K | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ENDV Stock